GLP-1 drug approvals: A breakdown
As of Oct. 17, the FDA has approved more than a dozen glucagon-like peptide-1 receptor agonists for diabetes, weight loss, cardiovascular disease and other indications. Becker's Hospital Review
As of Oct. 17, the FDA has approved more than a dozen glucagon-like peptide-1 receptor agonists for diabetes, weight loss, cardiovascular disease and other indications. Becker's Hospital Review